The PAX-BD study - COVID-19 information for study staff


Covid-19 has had a significant impact on clinical trials over the last few months. This page describes the steps taken to minimise COVID related risks to study staff in relation to the PAX-BD study.

In response to COVID-19 the PAX-BD study protocol has been updated to provide site teams with the flexibility to complete study activities via a number of different methods depending on site and participant preference. Sites will have been provided with all updated approval and study documentation to support this.

If site teams have any questions about the study and managing COVID risks please get in touch with the PAX-BD Trial Management Team using the details on the Contact page.